Start-up Coaching
Your contact
Dr. Petra Burgstaller
Incubation & MAxL Co-Lead, Portfolio Management
Christina Enke-Stolle
Incubation & MAxL Co-Lead, Partnership Management
Elisabeth Harbich
Project Management Start-up Support
Coaching for prospective entrepreneurs
Would you like to turn your biomedical research into a spin-off and build up a biotech start-up?
BioM accompanies you on the path from scientific idea to successful start-up. We support those interested in founding a company in transforming their research results into a sustainable business model - with individual advice, sound feedback, and practical know-how for biotech founding.
With many years of experience, a strong network, and a deep understanding of the specifics of the biotech industry, we want to offer founders the best possible support in turning scientific discoveries into successful biotech start-ups.
Our free initial consultation offers you:
- An assessment of your start-up project and business idea, as well as recommendations for next steps
- Advice on support programs and financing for biotech start-ups
- Access to an extensive network of industry contacts
When founding a biotech company, many questions arise at the outset. With our services, we want to help those interested in starting a business to reduce this complexity and put them on the right track - with clear biotech founding consulting.
More on the topic
09.01.2026
Ovo Labs announces world’s first rejuvenation of human eggs – hope for millions of aspiring parents
Ovo Labs, a pioneering biotechnology company from Oberschleißheim/Munich, has presented first-time efficacy data for its lead therapeutic EmbryoProtect 1 (EP1) at the UK’s largest fertility…
18.12.2025
BioM to Co-Host the 4th Session of Creative Destruction Lab (CDL) in Munich
BioM, together with its partner DEEP, the Institute for Deep Tech Innovation at ESMT Berlin, will co-host in Munich the 4th yearly session of Creative Destruction Lab (CDL), an…
16.12.2025
T-CURX raises 20 millions US-dollars series A to advance non-viral CAR-T cancer therapies
T-CURX announced a 20 Mio USD Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral in vivo CAR-T platform.
T-CURX GmbH,…